APA (7th ed.) Citation

Grünwald, V., Rußwurm, K., Eckert, R., Seseke, S., Standhaft, D., Hegemann, M., . . . Loehr, B. I. (2025). First-Line Treatment with Tivozanib for Metastatic Renal Cell Carcinoma in Real-World Settings Across Germany: Results of the Prospective, Non-Interventional, Post-Approval Study T-Rex. Cancers, 17(24), 3910. https://doi.org/10.3390/cancers17243910

Chicago Style (17th ed.) Citation

Grünwald, Viktor, et al. "First-Line Treatment with Tivozanib for Metastatic Renal Cell Carcinoma in Real-World Settings Across Germany: Results of the Prospective, Non-Interventional, Post-Approval Study T-Rex." Cancers 17, no. 24 (2025): 3910. https://doi.org/10.3390/cancers17243910.

MLA (9th ed.) Citation

Grünwald, Viktor, et al. "First-Line Treatment with Tivozanib for Metastatic Renal Cell Carcinoma in Real-World Settings Across Germany: Results of the Prospective, Non-Interventional, Post-Approval Study T-Rex." Cancers, vol. 17, no. 24, 2025, p. 3910, https://doi.org/10.3390/cancers17243910.